Eris Lifesciences reported a consolidated net profit of Rs 187.14 crore for the September 2026 quarter, up from Rs 134.47 crore a year ago. Revenue rose to Rs 892.37 crore. The results include significant non-recurring tax adjustments from a recent NCLT-approved scheme of arrangement and an exceptional write-down of Rs 35.90 crore related to past customer settlements.
Eris Lifesciences Posts Strong Q2 Growth Amid Structural Changes
Net Profit: Rs 187.14 crore | Revenue: Rs 892.37 crore
Reader Takeaway: Strong revenue growth offset by one-time tax gains and an exceptional settlement charge impacting the bottom line.
What just happened
Eris Lifesciences has released its consolidated financial results for the quarter ended September 30, 2026. The company reported a net profit of Rs 187.14 crore, reflecting a significant increase from Rs 134.47 crore in the same period last year. Revenue from operations reached Rs 892.37 crore compared to Rs 792.41 crore in Q2 of the previous year.
Why this matters
The profitability figures were heavily influenced by specific corporate developments. The company recognized a current tax credit of Rs 96 crore and a deferred tax charge of Rs 31 crore following the effectiveness of a Scheme of Arrangement on October 22, 2026. Conversely, the firm booked an exceptional item write-down of Rs 35.90 crore related to a customer settlement regarding products launched at risk in prior periods.
The backstory
The NCLT-approved Scheme of Arrangement involves the amalgamation of Aprica Healthcare Limited and the demerger of the 'Domestic Business' of Eris Oaknet Healthcare Private Limited into Eris Therapeutics Limited. This restructuring is designed to allow the company to set off business losses against profits and gain tax deductibility for brand asset amortization, which was reflected in the current quarter's tax positioning.
What changes now
Eris Lifesciences continues to expand its equity base through its ESOP programs, with 1,95,682 ordinary shares of Rs 1 each allotted during the half-year ended September 30, 2026. The company maintains an unmodified audit opinion from Walker Chandiok & Co LLP, indicating stable governance practices as it integrates its restructured business entities.
What to track next
Investors should monitor the long-term operational benefits of the recent business restructuring, particularly regarding the tax efficiency gains and the integration of the probiotics segment. Future quarters will clarify the normalized profit trajectory once these one-time tax and exceptional items are fully absorbed.